retatrutide phase 2 obesity nejm 2023 jastreboff (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive + osteoarthritis data we've ever seen in the 3 TRIUMPH-4 trial: Retatrutide Phase 3: TRIUMPH Program

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 17 randomised controlled trials

Li Y, Wang S, Li P, Li Y, Liu Y, Fang H, et al

What this means for you You'll need prior authorization, which requires: BMI 30 (or 27 with comorbidities) 6 months documented lifestyle efforts Possible step therapy (trying other medications first) Bottom line: Focus on meeting PA requirements

Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome